Calendar · pharmadog

Sign In Subscribe

Week of Apr 27, 2026

23

Apr 29, 2026phase 2 completion91d agoMassachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)N-acetylcysteine

Therapy area: Ophthalmology. Indication: Cataract, Fuchs Endothelial Corneal Dystrophy (FECD)

full page →N-acetylcysteine →source: globaldata

Apr 29, 2026phase 2 completion91d agoBangalore Medical College and Research Institute — dinoprostone (Phase II Trial Completion)dinoprostone ER

Therapy area: Dermatology. Indication: Vitiligo

full page →dinoprostone ER →source: globaldata

Apr 29, 2026phase 3 initiation91d agoAll India Institute of Medical Sciences Bathinda — mitomycin (Phase III Trial Initiation)Jelmyto

Therapy area: Ophthalmology. Indication: Open-Angle Glaucoma

full page →Jelmyto →source: globaldata

Apr 30, 2026constraining patent expiry europe90d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

full page →telavancin hydrochloride →source: globaldata

Apr 30, 2026filing90d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing90d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Choroidal Neovascularization

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing90d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing90d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Diabetic Retinopathy

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing90d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026phase 0 trial completion90d agoRuijin Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

Therapy area: Central Nervous System, Dermatology. Indication: Burns, Pain, Sedation

full page →dexmedetomidine →source: globaldata

Apr 30, 2026phase 0 trial completion90d agoShanghai Jiao Tong University — insulin (Phase 0 Trial Completion)insulin

Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

full page →insulin →source: globaldata

Apr 30, 2026phase 0 trial completion90d agoFoundation for the Promotion of Health and Biomedical Research of Valencia — Aquacel Ag + (Phase 0 Trial Completion)Aquacel Ag +

Therapy area: Dermatology. Indication: Pressure Ulcers

full page →Aquacel Ag + →source: globaldata

Apr 30, 2026phase 1 completion90d agoIlife Consulting Sarl — PST-611 (Phase I Trial Completion)PST-611

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Dry (Atrophic) Macular Degeneration, Geographic Atrophy

full page →PST-611 →source: globaldata

Apr 30, 2026phase 1 initiation90d agoJiangsu Vcare PharmaTech Co Ltd — VC-005 (Phase I Trial Initiation)VC-005

Therapy area: Dermatology. Indication: Atopic Dermatitis (Atopic Eczema)

full page →VC-005 →source: globaldata

Apr 30, 2026phase 1 initiation90d agoMerck & Co Inc — MK-6050 (Phase I Trial Initiation)MK-6050

Therapy area: Dermatology. Indication: Hidradenitis Suppurativa

full page →MK-6050 →source: globaldata

Apr 30, 2026phase 1 2 completion90d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 1 2 completion90d agoCentre International de Développement Pharmaceutique — afamelanotide (Phase I/II Trial Completion)afamelanotide

Therapy area: Dermatology. Indication: Vitiligo

full page →afamelanotide →source: globaldata

Apr 30, 2026phase 1 2 completion90d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

full page →MK-8748 →source: globaldata

Apr 30, 2026phase 2 completion90d agoVaidya Yagya Dutt Sharma Ayurvedic P. G. Mahavidhyalaya — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

Therapy area: Dermatology. Indication: Burns

full page →ayurvedic medicine →source: globaldata

Apr 30, 2026phase 2 completion90d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata

Apr 30, 2026phase 2 completion90d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

full page →ozonated oil →source: globaldata

Apr 30, 2026phase 2 completion90d agoJetema Co Ltd — JTM-102 (Phase II Trial Completion)JTM-102

Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

full page →JTM-102 →source: globaldata

Apr 30, 2026phase 2 completion90d agoChinese Academy of Medical Sciences Plastic Surgery Hospital — recombinant type III humanized collagen (Phase II Trial Completion)recombinant type III humanized collagen

Therapy area: Dermatology. Indication: Crow Feet, Unspecified Dermatological Disorders, Wrinkles, Xerosis (Dry Skin)

full page →recombinant type III humanized collagen →source: globaldata